Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u prethodnih 30 dana:20
  • preuzimanja u prethodnih 30 dana:11
članak: 1 od 1  
Medicinski časopis
2018, vol. 52, br. 4, str. 145-151
jezik rada: engleski
vrsta rada: pregledni članak
doi:10.5937/mckg52-18715


Poređenje efekata nistatina i flukonazola u lečenju oralne kandidijaze kod imunokompromitovanih osoba - sistemski pregledni rad
aUniverzitet u Kragujevcu, Medicinski fakultet
bVisoka zdravstvena škola strukovnih studija, Beograd, Zemun
cUniverzitet u Beogradu, Medicinski fakultet, Katedra za hirurgiju sa anesteziologijom + Institut za onkologiju i radiologiju Srbije, Klinika za onkološku hirurgiju, Beograd
dUniverzitet u Kragujevcu, Fakultet medicinskih nauka, Katedra za higijenu i ekologiju + Institut za javno zdravlje, Kragujevac

e-adresa: stajicdalibor@yahoo.com

Sažetak

Oralna kandidijaza je uobičajena gljivična infekcija u ustima imunokompromitovanih pojedinaca. Javlja se kad postoje idealni uslovi za njeno razmnožavanje i predstavlja prepreku ya pacijente. Tretman kandidijaze sastoji se od rešavanja faktora koji doprinose njenom nastanku, a osim toga i primene određenih antimikotičnih lekova - uključujući nistatin i flukonazol. Evaluacija efikasnosti ovih lekova važna je u sužavanju izbora lekova u terapiji. Svrha ove studije bila je upoređivanje efikasnosti nistatina i flukonazola u lečenju kandidijaze. Za ovu studiju su pretraživane dve baze podataka: PubMed i SCIndex da bi se pronašli radovi prikladnog sadržaja i doneo zaključak o ispunjavaju kriterijuma validnosti i značajnosti. U pretrazi radova korišćene su različite kombinacije ključnih reči na osnovu kojih su dobijene studije koje su se bavile upoređivanjem efikasnosti jednog od ova dva antifungalna leka. Nakon analize svih ovih studija, brojne studije koje su ispunile kriterijume validnosti i značaja svedene su na osam studija. Rezultati dobijeni upoređivanjem pokazali su da prednost u lečenju oralne kandidijaze ima flukonazol. Upotreba flukonazola u lečenju gljivične infekcije Candida albicans potpuno je bezbedna, a pacijenti koji su tretirani ovim lekom pokazali su duži period bez recidiva nego pacijenti tretirani nistatinom.

Ključne reči

nistatin; flukonazol; kandidijaza; oralna; imunokompromitovani organizam; terapija

Reference

Naknadno pridodat članak: provera, normiranje i linkovanje referenci u toku.
Cankovic M, Bokor-Bratic M. Infekcija kandidom albikans kod bolesnika sa oralnim planocelularnim karcinomom. Vojnosanit pregl 2010; 67:766-70.
Janković Lj. Oralna medicina. Beograd: Zavod za udžbenike i nastavna sredstva, 2007.
Gulati M, Nobile CJ. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect 2016; 18:310-21.
Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002; 78:455-9.
Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther 1998; 20:40-57.
Niimi M, Firth NA, Cannon RD. Antifungal drug resistance of oral fungi. Odontology 2010; 98:15-25.
Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2002; CD002033.
American Medical Association, AMA Department of Drugs. AMA Drug Evaluations. 3rd ed. Littleton: PSG Publishing Co., Inc., 1977.
Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of candida infection following liver transplantation. J Infect Dis 1996; 174:583-8.
Lyu X, Zhao C, Yan ZM, Hua H. Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Des Devel Ther 2016; 10:1161-71.
Nenoff P, Krüger C, Schaller J, Ginter-Hanselmayer G, Schulte-Beerbühl R, Tietz HJ. Mycology - an update Part 2: Dermatomycoses: Clinical picture and diagnostics. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2014; 12:749-77.
Picciani BL, Michalski-Santos B, Carneiro S, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol 2013; 68:986-91.
Miller DJ. Diagnosis and management of Candida and other fungal infections of the head and neck. Curr Infect Dis Rep 2002; 4:194-200.
Cuenca-Estrella M, Verweij PE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18:9-18.
Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24:1204-7.
Sackett DL, Straus SE, Richardson WS. Evidencebased medicine: how to practice and teach EBM. 2nd ed. New York: Churchill Livingstone, 2000.
Sheridan DJ, Julian DG. Achievements and limitations of evidence-based medicine. J Am Coll Cardiol 2016; 68: 204-13.
Pagani JL, Chave JP, Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother 2002; 50:231-40.
Hamza OJ, Matee ML, Brüggemann RJ, et al. Singledose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. Clin Infect Dis 2008; 47:1270-6.
Groll AH, Just-Nuebling G, Kurz M, et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997; 40:855-62.
Laverdiere M, Rotstein C, Bow EJ, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. J Antimicrob Chemother 2000; 46:1001-8.
Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients with nystatin. Cochrane Database Syst Rev 2014; CD002033.
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014; 371:326-38.
Mersal A, Alzahrani I, Azzouz M, et al. Oral nystatin versus intravenous fluconazole as neonatal antifungal prophylaxis: non-inferiority trial. J Clin Neonatol 2013; 2:88-92.